Valneva

Crucell Sweden is a biotechnology company that specializes in the development, manufacturing, and distribution of vaccines. It offers contract manufacturing services to vaccine companies both in Sweden and internationally. The company is involved in producing biological bulk materials and active pharmaceutical ingredients (API), as well as finished vaccine products for clinical trials and market supply. Additionally, Crucell Sweden focuses on developing antibodies aimed at preventing and treating infectious diseases, contributing to public health efforts through innovative vaccine solutions.

BliNK Biomedical SAS, established in 2014 and based in Lyon, France, is a biotechnology company focused on the discovery and development of novel monoclonal antibody therapies for life-threatening diseases like cancer, with an emphasis on immuno-oncology targets. The company's proprietary B cell technology platform facilitates the efficient isolation of antibody-producing cells from various species, enabling the identification of unique therapeutic antibodies even for challenging targets. BliNK's lead program involves a monoclonal antibody targeting an immune checkpoint to stimulate the body's immune response against tumors.